. Furthermore, in vitro autoradiography using [3H]DMI visualizes NE uptake sites (Biegon and Rainbow, 1983) . Sodium-sensitive cocaine binding to striatal membranes may in part label DA uptake sites (Kennedy and Hanbauer, 1983) , although the relatively low affinity of cocaine for the binding sites makes a detailed evaluation difficult.
Mazindol, a clinically employed appetite suppressant, potently inhibits both NE and DA uptake (Heikkila et al., 1977; Hyttel, 1982) .
[3H]Mazindol labels both DA and NE uptake sites in rat brain homogenates (Javitch et al., 1983; 1984) . DMI at appropriate concentrations selectively abolishes [3H]mazindol binding to NE uptake sites without significantly affecting binding to DA uptake sites (Javitch et al., 1984) . In the present study, we have differentially visualized sites associated with NE and DA uptake utilizing [3H]mazindol autoradiography in the presence or absence of DMI.
Materials and Methods
[3H]Mazindol (11 Ci/mmol) was supplied by New England Nuclear, Boston, MA. Sources of other drugs were as described previously (Javitch et al., 1984) . Male Sprague-Dawley rats (150 to 200 gm) were anesthetized with pentobarbltal and perfused via the left ventricle of the heart with 0.9% NaCI, 50 mM sodium phosphate, pH 7.5, followed by 50 mM sodium phosphate and 0.3 M sucrose. Brains were removed, embedded in brain paste, and rapidly frozen at -70°C on microtome chucks. Sections (8 PM) were cut at -15°C and thaw-mounted on gelatin-coated slides. The slides were dessicated and then stored at -20°C. For autoradiographic studies, sections were preincubated at 4°C for 5 mln in 50 mM Tris buffer (pH 7.9 at 4"C, containing 120 mM NaCI, 5 mM KCI) and then incubated for 40 min at 4°C in the assay buffer (50 mM Tris, pH 7.9, at 4"C, 300 or 120 mM NaCI, 5 mM KCI) with 4 nM [3H] (Javitch et al., 1983; 1984) . Specific binding of high-affinity component displaying a K, of about 10 nM (Fig. 2 ). This 4 nM [3H]mazindol at 300 mM NaCl is about 70% of total binding in high-affinity component reflects binding to NE uptake sites (Javitch the caudate-putamen.
Scatchard analysis reveals a single compoet al., 1984 (Fig. 3) binding to NE uptake sites is about 25% of its K. for DA uptake sites, the values presented represent roughly half the maximal number of NE uptake sites but only one-eighth the number of DA uptake sites. Binding levels in each region were determined using computer-assisted microdensitometry (Kuhar et al., 1984) . Values represent the means of determinations in 2 to 5 areas in representative sections from each of two animals, which varied less than 20%. Density is described on a scale from 0 to 5 where each level is defined as follows: 0, 0 to 0.04 pmol/mg protein: 1, 0.04 to 0.2 pmol/mg protein; 2, 0.2 to 0.5 pmol/mg protein; 3, 0.5 to 0.9 pmol/mg protein; 4, 0.9 to 1.5 pmol/mg protein; 5, 1.5 to 2 pmol/mg protein. (Strittmatter et al., 1984) .
Discussion
[3H]Mazindol labels both DA and NE uptake sites (Javitch et al., 1983; 1984) . The KD and B,, values as well as drug potencies in blocking [3H]mazindol binding to brain slices agree with values obtained in brain homogenates (Javitch et al., 1983 (Javitch et al., , 1984 . Moreover, ionic requirements for binding to slices and homogenates are similar and resemble those for [3H]DA accumulation into striatal synaptosomes (Holz and Coyle, 1979) .
It is possible to separate the dopaminergic and noradrenergic components of [3H]mazindol binding using 0.3 FM DMI, a concentration sufficient to abolish binding to NE uptake sites without significantly affecting binding to DA uptake sites (Javitch et al., 1984) . The regional distribution of DMI-sensitive specific [3H]mazindol binding closely resembles the localization of noradrenergic cell bodies and terminal projections as demonstrated by dopamine phydroxylase immunohistochemistry and catecholamine histofluorescence (Fuxe, 1965; Ungerstedt, 1971; Hartman et al., 1972; Hartman, 1973; Swanson and Hartman, 1975; Moore and Bloom, 1979; Biegon and Rainbow, 1983; Lindvall and Bjorklund, 1983) . In contrast, the DMI-insensitive component of specific [3H]mazindol binding parallels the distribution of dopaminergic neurons and their projections (Fuxe, 1965; Moore and Bloom, 1978; Lindvall and Bjorklund, 1983) .
The high levels of DMI-insensitive specific [3H]mazindol binding to caudate-putamen, nucleus accumbens, and olfactory tubercle are to uptake sites on the terminals of DA neurons originating in the SN and VTA. This conclusion is supported by the success of colchicine, ibotenic acid (Schwartz et al., 1979) or 6-OHDA (Breese and Traylor, 1979) lesions of the SN/VTA region to profoundly decrease DMI-insensitive specific [3H]mazindol binding to the ipsilateral caudate-putamen.
High levels of DMI-insensitive specific [3H]mazindol binding are seen in the subthalamic nucleus, which contains moderate levels of DA (Versteeg et al., 1976) and catecholamine fibers (Brown et al., 1979; Meibach and Katzman, 1979) . [3H]Mazindol binding to the SN pars reticulata reflects the substantial levels of DA uptake into dendrites of this region (Geffen et al., 1976) . High levels of [3H] mazindol binding to DA uptake sites occur in the SN pars compacta and VTA, the origins of the mesotelencephalic dopaminergic system. [3H]Mazlndol (4 nM) bIndIng to tissue sections was performed as described in "Materials and Methods" In the presence of 120 mM NaCI. Lesions were performed as described tn "Materials and Methods." Binding levels were determined using computer-assisted microdensitometty (Kuhar et al., 1984) . While DA concentrations in these regions are only IO to 20% of those in the caudate-putamen, specific [3H]mazindol binding to DA uptake sites In these cell body containing areas is 30 to 50% of that in the caudate-putamen.
This finding fits with studies showing a higher ratio of DA uptake to endogenous DA concentration in cell body areas than in terminal areas (Geffen et al., 1976; Beat-t et al., 1979; Beart and McDonald, 1980) . Proportionally higher amine uptake in cell bodies than in terminals may reflect ongoing synthesis of uptake sites at the rough endoplasmic reticulum of the cell body prior to their transport to terminal areas. Transmitter presumably accumulates primarily in mature secretory granules of terminals.
While comparable concentrations of DA are found in the caudateputamen and median eminence, the ratio of [3H]mazindol binding to DA uptake IS 10 times higher in caudate-putamen, agreeing with the proportionally lower [3H]DA uptake into synaptosomes prepared from median eminence (Cuello et al., 1973; Cuello and Iversen, 1973; Demarest and Moore, 1979) . As DA is released from tuberohypophyseal dopaminergic neurons into the portal blood vessels, there may be less need to inactivate synaptic levels of transmitter via reuptake. Fewer uptake sites may explain the difficulty in destroying DA cells in the tuberohypophyseal system with 6-OHDA (Cuello et al., 1974) . The low level of [3H]mazindol binding to DA uptake sites in the median eminence is paralleled by similar low levels in the arcuate nucleus, the site of origin of the tuberohypophyseal system.
Other regions with substantial DMI-insensitive specific [3H]mazindol binding correlate with the projection of DA neurons. The lateral habenula contains a dense collection of catecholaminergic axons, as well as substantial DA concentrations (Lindvall and Bjorklund, 1983; Versteeg et al., 1976) . Tyrosine hydroxylase immunohistochemistry has also demonstrated a catecholaminergic fiber system in this location (Lindvall and Bjorklund, 1983) . Furthermore, DMIinsensitive DA uptake has been measured in the lateral habenula (Lindvall and Bjorklund, 1983) .
The lateral septal nucleus is innervated by a dopaminergic projection from the VTA as is the bed nucleus of the stria terminalis (Moore and Bloom, 1978; Lindvall and Bjorklund, 1983) . There is also a dopaminergic innervation of the amygdala originating in the VTA and medial SN (Lindvall and Bjorklund, 1983) . Binding to DA uptake sites in hypothalamic regions, the thalamus, and septum is probably associated with the periventricular and incertohypothalamic DA systems (Lindvall and Bjorklund, 1983) . DMI-insensitive [3H]mazindol binding to locus coeruleus presumably reflects uptake sites on the terminals of dopaminergic neurons in the mesopontine system (Lindvall and Bjorklund, 1983) . Cerebral cortical areas are innervated by the mesocortical dopaminergic system (Moore and Bloom, 1978; Lindvall and Bjorklund, 1983) , explaining DMI-insensitive [3H]mazindol binding to cerebral cortex. The anterior olfactory nuclei are also innervated by a projection from the medial SN and VTA (Lindvall and Bjorklund, 1983) .
DMI-sensitive specific [3H]mazindol binding is densest in the locus coeruleus, the site of origin of many noradrenergic neurons (Moore and Bloom, 1979; Lindvall ,and Bjorklund, 1983) . The very high levels of binding to NE uptake sites in this cell body area may reflect the same sort of factors that operate in DA cell body areas. The high densities of binding in the nucleus of the solitary tract also may be associated with catecholamine cell bodies.
Although catecholaminergic systems have been visualized by tyrosine hydroxylase and dopamine P-hydroxylase immunohistochemistry and catecholamine histofluorescence, [3H]mazindol autoradiography provides several advantages over these techniques. Autoradiography independently and quantifiably labels both norepinephrine and dopamine uptake systems. Furthermore, the concerted Vol. 5, No. 6, June 1985 
